Risk Management: Prescribing Controlled Substances: Managing the Risks

Conclusion Using the three Cs of risk management strategies—collecting information, communicating, and carefully documenting—when prescribing controlled substances supports quality patient care and can decrease the risk of improper prescribing allegations. Appendix 1. Prescribing Controlled Substances: Informed Consent Some, but not all states have promulgated various requirements and recommendations for components of an informed consent discussion when prescribing controlled substances.  The following is a compilation of current individual state requirements and recommendations for informed consent.  Prescribers should determine the state requirements for their state, and may want to consider incorporating these components: The physician shall obtain written, informed consent and discuss the risks and benefits of the use of controlled substances with the patient; persons designated by the patient; or the patient’s surrogate or guardian if the patient is incompetent. Ensure the patient does not have any absolute contraindications and review risks and benefits related to any relative contraindications with the patient. The treatment plan, any alternatives to controlled substance therapy, additional therapies to be used in conjunction with controlled substances (if any) should be reviewed. Inform the patient of the risks of addiction, physical dependence, and abuse; the potential for dose escalation/tolerance. Inform the patient of the risk of the p...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Risk Management Source Type: research

Related Links:

Publication date: September 2020Source: Social Science &Medicine, Volume 260Author(s): J.M. Bowles, L.R. Smith, S.R. Verdugo, K.D. Wagner, P.J. Davidson
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
To what extent does male alcohol consumption impact a couple's time to pregnancy?Human Reproduction
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
As coronavirus cases surge across the US, doctors and nurses are telling CNN there's still a dire shortage of protective equipment, especially masks. Critics say the Trump administration isn't properly using a law that could help alleviate the shortage. CNN's Drew Griffin reports
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Middle-aged people in the United States are in worse health than those living in England, and the disparities are larger for low income individuals, according to a new study. This gap could point to why Covid-19 has had a more devastating impact on low income Americans.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
The Trump administration is pushing to fully reopen schools across the nation despite growing coronavirus numbers, but health officials say plans need to be made to keep families safe. Dr. Dyan Hes, a pediatrician and founder of Gramercy Pediatrics in New York City, joins CBSN's "Red&Blue" to discuss.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Source: Reuters: Health - Category: Consumer Health News Source Type: news
Source: Reuters: Health - Category: Consumer Health News Source Type: news
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Academies | Addiction | Alcoholism | Allergy & Immunology | Appendicitis | Brain | Child Abuse | Children | Chronic Pain | Continuing Medical Education | Databases & Libraries | Depression | Education | Emergency Medicine | Environmental Health | Epidemics | Epidemiology | Health Insurance | Hydrocodone | Insurance | Laboratory Medicine | Legislation | Malpractice | Neurology | Neuroscience | Overdose | Pain | Pain Management | Patient Communication | Pregnancy | Psychiatry | Psychology | Respiratory Medicine | Suboxone | Substance Abuse | Substance Abuse Disorders | Universities & Medical Training | USA Health | Warnings